Clinical pharmacology of moxalactam in patients with malignant disease.
AUTOR(ES)
Estey, E H
RESUMO
Pharmacological studies of moxalactam were conducted with 37 cancer patients. Intramuscular administration of 500 mg of moxalactam to 10 patients produced a mean peak serum concentration of 12.4 micrograms/ml. The serum terminal-phase half-life was 3.9 h. Intravenous administration of 500 mg of moxalactam over 5 min to the same 10 patients produced a mean serum concentration of 42.0 micrograms/ml at 15 min, which decreased to 3.3 micrograms/ml at 6 h. A dose of 1 g of moxalactam was given in an identical manner to the same 10 patients. The mean serum concentration was 69.7 micrograms/ml at 15 min and 7.4 micrograms/ml at 6 h. The mean proportions of a drug recovered in the urine by 12 h after administration were 59% after the intramuscular dose and 61 and 55% after the single intravenous doses. Multiple-dose intravenous studies were also conducted. The serum terminal-phase half-life varied from 2.0 to 3.2 h. Continuous infusion studies were performed by up to 9 days by using a loading dose of 1 g over 0.5 h, followed by 2 g every 6 h. Serum concentrations were maintained at about 30.0 micrograms/ml during the study period.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=181493Documentos Relacionados
- Clinical Pharmacology of Ceftriaxone in Patients with Neoplastic Disease
- Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease.
- Immunocytochemical staining with monoclonal antibodies in cytologically "negative" serous effusions from patients with malignant disease.
- Neuroleptic malignant syndrome in a patient with Wilson's disease.
- Terminal care in malignant disease.
